Nektar Therapeutics
Status: Publicly traded
Direct answer
Nektar Therapeutics is publicly traded on NASDAQ under the ticker NKTR.
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck...
Can you invest in Nektar Therapeutics?
Yes. Nektar Therapeutics is publicly traded on NASDAQ under the ticker NKTR.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Nektar Therapeutics
Detailed equity research is provided by MarketSnap.